<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312401</url>
  </required_header>
  <id_info>
    <org_study_id>14-172</org_study_id>
    <nct_id>NCT02312401</nct_id>
  </id_info>
  <brief_title>Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy</brief_title>
  <official_title>Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand prostate cancer changes after radiation&#xD;
      treatment, through magnetic resonance imaging (MRI). MRI is an imaging test that allows&#xD;
      doctors to see prostate gland without any operation procedures. It can help identifying the&#xD;
      tumors in the prostate. For patients with newly diagnosed prostate cancer, MRI may help&#xD;
      doctors manage treatment better and sooner.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>characterize the changes in tumor characteristics by functional imaging changes with post-treatment prostate biopsy outcomes</measure>
    <time_frame>at 24 months after completion of radiotherapy</time_frame>
    <description>This change will then be correlated with the biopsy outcome (binary) by two sample t-tests.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Multiparametric MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 &amp; 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>multi-parametric MRI(MP-MRI)</intervention_name>
    <arm_group_label>Multiparametric MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>dynamic contrast-enhanced MRI (DCE)</intervention_name>
    <arm_group_label>Multiparametric MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <arm_group_label>Multiparametric MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biopsy proven (completed and/or reviewed at MSK) adenocarcinoma of the&#xD;
             prostate, who will undergo external beam radiotherapy using conventional fractionation&#xD;
             IGRT including moderate hypofractionated radiation, low rate brachytherapy alone,&#xD;
             brachytherapy (either high dose or low dose) combined with supplemental image guided&#xD;
             radiation (including IGRT, EBRT, and SBRT), SBRT, or proton radiotherapy.&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Baseline MP-MRI, which is obtained at MSKCC Main Campus on the 3-Tesla Philips MRI&#xD;
             unit as part of the standard (clinical) staging assessment demonstrates at least one&#xD;
             dominant or visible lesion which measures &gt; 0.5 cm in maximum axial diameter as&#xD;
             assessed on T2-weighted images.&#xD;
&#xD;
          -  No prior history of androgen deprivation therapy within the last month. However&#xD;
             patients who will receive neoadjuvant and concurrent and adjuvant hormonal therapy&#xD;
             will be eligible.&#xD;
&#xD;
          -  Willing to come to MSK Main Campus for baseline and follow-up MP-MRIs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of radical prostatectomy&#xD;
&#xD;
          -  Patients who are unwilling or unable to undergo MRI including patients with&#xD;
             contraindications to MRI such as the presence of cardiac pacemakers or non-compatible&#xD;
             intracranial vascular clips, claustrophobia, inability to lie flat for the duration of&#xD;
             the study etc.&#xD;
&#xD;
          -  Patients with a metallic hip implant, metallic implant or device in the pelvis or&#xD;
             ferromagnetic fiducial beacons (Calypso) that might distort local magnetic field and&#xD;
             compromise quality of MP-MRI&#xD;
&#xD;
          -  Patients in which gadolinium contrast is contra-indicated.&#xD;
&#xD;
          -  Metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zelefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Zelefsky, MD</last_name>
    <phone>212-639-6802</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hebert A. Vargas, MD</last_name>
    <phone>212-639-4017</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
    <investigator>
      <last_name>Michael Zelefsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>14-172</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

